Korean biotechs snatch U.S. stem cell manufacturing facility

Date Published02/13/2019
Author NameEric Palmer
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name CoImmune1
Parent companyGenexine
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Capital investment ($):11.1
Country(ies) from which reshored:Korea, Republic of
City reshored to:Durham
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredimmunotherapies
What domestic positive factors made reshoring more attractive?Automation/technology, Proximity to customers/market, Under-utilized capacity
Find Reshoring Articles